Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In this study, we showed that simultaneous genetic disruption of the ubiquitin ligase SHPRH and FANC, one of core factors in the Fanconi Anemia (FA) pathway, substantially rescued hypersensitivity towards cisplatin, an inter-strand cross-linking (ICL) agent. This observation suggests that SHPRH-dependent pathway antagonizes to the FA pathway. We also showed that PARP-1 prohibits resection in in vitro extract assay and that low expression of CtIP nuclease in breast cancer correlates with poor prognosis and hypersensitivity towards PARP inhibitors.
|